|
|
Volumn 24, Issue 3, 2006, Pages 268-269
|
|
Biogenerics at the crossroads
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOGENERIC DRUG;
BIOLOGICAL PRODUCT;
ERYTHROPOIETIN;
GENERIC DRUG;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
INSULIN;
INTERFERON;
UNCLASSIFIED DRUG;
BIOTECHNOLOGY;
CONSUMER;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE ACCESS;
IMMUNOGENICITY;
NOTE;
PATENT;
PRESCRIPTION;
PRIORITY JOURNAL;
UNITED STATES;
ARTICLE;
DRUG INDUSTRY;
DRUG LEGISLATION;
LEGAL ASPECT;
PHARMACEUTICS;
BIOPHARMACEUTICS;
BIOTECHNOLOGY;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUGS, GENERIC;
LEGISLATION, DRUG;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 33644862556
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0306-268a Document Type: Note |
|
Times cited : (16)
|
|
References (0)
|
